International Pharma Companies Pharmaceuticals Small Molecule 
Drug Discovery World
SEPTEMBER 29, 2022
In this listicle, SAMDITech outlines the benefits of outsourcing models in the pharmaceutical industry, looking past perceived costs to the value outsourcing can bring. . Many companies have several projects ongoing simultaneously, which can limit internal resources (space, lab equipment, personnel) and delay progress.
Drug Discovery World
OCTOBER 16, 2023
A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. billion in funding.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
APRIL 27, 2023
Dr Mansley also comments that the multitude of biotech and pharma companies in the Greater Boston region means that people regularly move organisations. She said: “When one of our customers leaves a company and moves to a new one up the street, they often get in touch with us, which helps us grow new business.
The Pharma Data
DECEMBER 17, 2020
Hartfield previously served as CEO of Vitae Pharmaceuticals prior to its acquisition by Allergan. X4 Pharmaceuticals – Diego Cadavid was named chief medical officer of Boston-based X4 Pharmaceuticals. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.
Drug Discovery World
AUGUST 5, 2022
An increasing number of academic groups, start-ups, biotechs and small pharma companies are turning to external consultants for professional programme management support and guidance to help them progress their ideas into medicines for patients. One of these may be lack of internal resources to carry out particular tasks.
Drug Discovery World
JANUARY 3, 2023
In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. Most major pharma companies operate DEL platforms, and several service providers offer DEL capabilities to companies that outsource their DEL activities.
Drug Target Review
APRIL 19, 2024
Sibylla’s scientific founders come from very different scientific fields that do not usually speak to each other, such as theoretical physics, molecular biology and pharmaceutical chemistry. We also have collaborations with pharmaceutical companies where we leverage the best of our unique platform and pharma expertise on the target.
Expert insights. Personalized for you.
130 
Let's personalize your content